Quotes 5-day view Delayed Nasdaq
06/17/2022
06/21/2022
06/22/2022
06/23/2022
06/24/2022
Date
44.14(c)
45.76(c)
45.9(c)
46.8(c)
46.9(c)
Last
2 395 696
884 739
959 114
1 310 956
3 186 782
Volume
+2.39% +3.67% +0.31% +1.96% +0.21% Change
Estimated financial data (e) (USD)
Sales 2022
715 M - -
Net income 2022
279 M - -
Net Debt 2022
-
-
-
P/E ratio 2022
20,6x
Yield 2022
-
Sales 2023
901 M - -
Net income 2023
352 M - -
Net Debt 2023
-
-
-
P/E ratio 2023
17,1x
Yield 2023
-
Capitalization
6 462 M 6 462 M -
Capi. / Sales 2022
9,04x
Capi. / Sales 2023
7,17x
Nbr of Employees
145
Free-Float
98,8%
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’...
Ratings of Halozyme Therapeutics, Inc.
All news about HALOZYME THERAPEUTICS, INC.
06/15 TRANSCRIPT : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..CI
06/10 Genmab Seeks $405 Million in New Arbitration With Janssen MT
06/10 Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen MT
06/08 Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference PR
06/07 Halozyme Therapeutics Launches Testosterone Replacement Therapy Drug Tlando MT
06/07 Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testostero.. PR
06/07 Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment fo.. CI
05/26 Goldman Sachs Raises Halozyme Therapeutics' Price Target to $60 From $48, Buy Rating Ke.. MT
05/24 HALOZYME THERAPEUTICS : Completes Antares Pharma Acquisition - Form 8-KPU
05/24 HALOZYME THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Ac..AQ
05/24 Halozyme Completes Antares Pharma Acquisition PR
05/23 Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc.. CI
05/12 Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition MT
05/12 Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR
05/11 JMP Securities Raises Halozyme Therapeutics Price Target to $58 From $55, Maintains Mar.. MT
News in other languages on HALOZYME THERAPEUTICS, INC.
Analyst Recommendations on HALOZYME THERAPEUTICS, INC.
Chart HALOZYME THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends HALOZYME THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
9
Last Close Price
46,90 $
Average target price
55,00 $
Spread / Average Target
17,3%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
